(Open access funding provided by Semmelweis University)
Subjects:
Psychiatry
The quantity and quality of real-world data and real-world evidence in schizophrenia
research are at a high level. However, these results are not included in the grading
systems used to develop treatment guidelines for schizophrenia. A meta-analysis and
a network meta-analysis have independently provided evidence that the results of randomized
clinical trials in schizophrenia adequately translate to real-world settings. The
authors propose the incorporation of a synthesis of evidence derived from analyses
of randomized controlled trials and real-world data as a novel and highest level of
evidence in grading instruments used to develop treatment guidelines for schizophrenia.
